SNMMI Curriculum VL

Modulation of PSMA Expression by Androgen Deprivation Therapy (ADT) - Louise Emmett

Details
Louise Emmett presents on the modulation of prostate-specific membrane antigen (PSMA) expression by androgen deprivation therapy (ADT). The study is comprised of serial PSMA PET in men with either hormone-sensitive or castrate-resistant prostate cancer commencing androgen blockade. PSMA may be targeted for either diagnostic and therapeutic purposes in the management of prostate cancer. Dr. Emmett...

Bone Targeted Theranostics with 18F-NaF/ 223Ra Cl2 in Prostate Cancer - Hossein Jadvar

Details
Hossein Jadvar presents on the use of sodium fluoride and radium-223 as a theranostic pair in the treatment of patients with metastatic prostate cancer. 18 F-sodium fluoride has experienced a remarkable recent renaissance in the management of neuroendocrine tumors and prostate cancer. Dr. Jadvar presents this information during the annual meeting of the Society of Nuclear Medicine and Molecular Im...

Non-PSMA Based Theranostics in Prostate Cancer - Andrei Iagaru

Details
Andrei Iagaru speaks on non-PSMA based theranostics in prostate cancer. Dr. Iagaru covers gastrin-releasing peptide receptors, part of the bombesin family, which are overexpressed in many cancers including prostate cancer. Targeting tumor-expressed receptors using selective molecules for diagnostic, therapeutic or both diagnostic and therapeutic purposes is a promising approach in oncological appl...

Radiotherapy Planning in Prostate Cancer Patients - Matteo Sepulcri and Laura Evangelista

Details
Matteo Sepulcri and Laura Evangelista present on radiotherapy in prostate cancer patients. Together they touch on subjects such as radiotherapy treatments for prostate cancer and the role of PET/CT in different stages of prostate cancer. This presentation took place as part of the annual Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting. Biographies: Matteo Sepulcri, Radiation Onco...

Reproducibility and Repeatability of Quantitative FDHT Uptake Metrics in CRPC - Andrew Scott

Details
Andrew Scott, MD presented a multinational trial looking at a fluorodihydrotestosterone (FDHT) in patients with castration-resistant prostate cancer on behalf of colleagues from a number of institutions. The intent was that they would look at whether or not this was a test which could be reliably introduced in individual patients at multiple centers in multiple continents, and whether or not there...

Early Initiation of Lu177 PSMA Radioligand Therapy Prolongs Survival in Metastatic PCa - Harshad Kulkarni

Details
Where in this treatment regimen would you place lutetium-177-PSMA radioligand therapy? This was the question Harshad Kulkarni, MD posed to the audience at the start of his presentation. The aim of the study which he was presenting during this Society of Nuclear Medicine and Molecular Imaging presentation was to determine the influence of timing of lutetium PSMA radioligand therapy in metastatic pr...

Initial Experience with Actinium- 225 PSMA in Advanced Prostate Cancer - Machaba Michael Sathekge

Details
Mike Machaba Sathekge, MD, PhD presents on the power of medicine, specifically targeted radionuclide therapies and the use of actinium-225 in advanced prostate cancer. Targeted α-therapy with 225Ac-PSMA-617 although still preliminary, has demonstrated strong potential to significantly benefit advanced-stage prostate cancer patients. He discusses the initial experience with 225Ac-PSMA-617 in a deve...

Prognostic Value of Baseline Imaging Parameters Prior to LuPSMA Therapy - Justin Ferdindandus

Details
At the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual conference, Justin Ferdindandus presents the results of a study which evaluated whether baseline imaging can provide prognostic information in patients treated with lutetium PSMA regarding overall survival and progression-free survival. The post-hoc analysis revealed that a favorable response by the means of a 50% PSA d...

Radium 223 Dichloride Use in Patients with Castrate Resistant Prostate Cancer - Hossein Jadvar

Details
Hossein Jadvar joins Phillip Koo for the last in its series of video presentations in the Society of Nuclear Medicine SNMMI video lecture series. Dr. Jadvar presents on the topic of Radium 223 dichloride use in patients with castrate-resistant prostate cancer. (Length of Interview: 34 min) Biographies: Phillip J. Koo, MD is the Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer...

SNMMI Osseous Scintigraphy - Ephraim E. Parent

Details
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) presents the Prostate Cancer Imaging and Therapy curriculum. In this continuing education session, Dr. Ephraim Parent joins Dr. Phil Koo to present and discuss bone imaging and the role in prostate cancer, specifically bone scintigraphy. His presentation outlines an overview of Radiopharmaceuticals that are used for bone imaging, planar...